Purpose Severe adverse events frequently occur in patients treated with sorafenib, whereas
some patients have suboptimal response to sorafenib. We aimed to evaluate the association …

Background Treatment outcome of children with pediatric hepatocellular carcinoma (pHCC)
is poor. Therefore, we evaluated the tyrosine kinase inhibitor sorafenib in a model of pHCC …

Sorafenib targets the Raf/mitogen-activated protein kinase, VEGF, and platelet-derived
growth factor pathways and prolongs survival patients in advanced hepatocellular …

Background: Sorafenib is a potent inhibitor against Raf kinase and several receptor tyrosine
kinases that has been approved for the clinical treatment of advanced renal and liver cancer …

HepG2 cells were exposed to sorafenib, irinotecan, and oxaliplatin and then subjected to
MTT assay to determine chemosensitivity. Flow cytometry was used to examine cell cycle …

Although sorafenib was approved as antiangiogenic agent in case of hepatocellular
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a particularly vascularized solid
tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this …

Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but
its use is hampered by the occurrence of drug resistance. To investigate the molecular …

Background Patients with advanced hepatocellular carcinoma (HCC) who received second
line sorafenib plus doxorubicin following disease progression on sorafenib were shown …

Novel therapeutic strategies are needed to treat patients with advanced hepatocellular
carcinoma (HCC). Combination therapy of sorafenib and type I interferon (IFN) has …